Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Gastrointestinal Tumor Research and Treatment, and Lung Cancer Treatments and Mutations.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).
Estimating overall survival by combining administrative and hospital death data: a methodological challenge.
COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.
Outcome and recurrence patterns of low-risk gonadal germ cell tumors in children and adolescents
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
Evaluation of different algorithms for automatic segmentation of head-and-neck lymph nodes on CT images.
Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 study
Comparison between exclusive (chemo)radiation and surgery or induction chemotherapy as first curative treatment for localized or locally advanced head and neck squamous cell carcinomas (L(A)-HNSCC): Sub-analysis of the EPOCKS study
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy – including photon and proton therapy – for the treatment of radioresistant tumors: the ETOILE trial
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network